This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
CRD commentary

Interventions:
The comparators were appropriately selected as the proposed treatment was added to the standard care in the authors' setting. A full description of the two strategies would have been useful to determine their relevance for other health care systems.
Effectiveness/benefits:
The clinical data were from a RCT, and this design is generally considered to provide valid evidence due to features such as the random allocation of patients, blinding of researchers to allocation, and the ITT principle. The study groups were comparable at baseline in their clinical and sociodemographic factors and statistical tests were used to adjust the results for these baseline characteristics. A relatively high number of patients provided data at follow-up (76 from an initial 106), but the authors acknowledged that the lack of statistical significance in the clinical endpoints could have been due to a lack of power from this sample size. This was a potential limitation of the analysis. A validated instrument was used to assess the impact of the interventions on the patients' quality of life, but the EQ-5D scores were similar and a formal assessment of QALYs was not carried out.
Costs:
The economic analysis was conducted from a broad perspective and various items were included. Extensive details of resource use and unit costs were provided, but there was limited information on the sources of costs and the price year and discounting were not reported. Conventional statistical tests were carried out to assess the significance of the cost differences and to exclude outliers, as a large amount of hospital services were used by two patients.
Analysis and results:
The results were extensively presented. A synthesis of the costs and benefits was not performed, as the economic and clinical results were similar between the two groups. The uncertainty was not investigated in conventional sensitivity analyses, but statistical tests were performed to calculate confidence intervals around the mean differences in costs and benefits. Wide ranges of values were observed for both clinical and economic outcomes, suggesting great uncertainty. The exclusion of outliers provided less variable estimates, but they remained not statistically significant. Given this lack of statistical significance and the large variability, a cost-effectiveness acceptability curve would have been interesting to show the probability of CBT being cost-effective. There was a strong trend for better clinical outcomes and costs for
